PepGen

PepGen Net Margin

Net Profit Margin of PepGen (PEPG) as of Nov 19, 2026.

Net Margin

-

Last updated:

Net Profit Margin of PepGen is 2026 - . Net Profit Margin of PepGen was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PepGen Stock analysis

What does PepGen do? PepGen Inc., based in Cambridge, Massachusetts, is a biotechnology company focused on developing oligonucleotide therapies for neuromuscular and neurologic diseases. The company utilizes its enhanced delivery oligonucleotide (EDO) platform, which employs cell-penetrating peptides to enhance therapeutic delivery. Its lead candidates, PGN-EDO51 for Duchenne muscular dystrophy and PGN-EDODM1 for myotonic dystrophy type 1, are part of a pipeline targeting degenerative conditions. Listed on 6 May 2022, PepGen operates with a team of 56 employees. PepGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PepGen stock

On Eulerpool you can find the complete historical development of Net Profit Margin PepGen since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's PepGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — PepGen

All Key Metrics — PepGen